Company Profile
Jaguar Health Stock Price, News & Catalysts
- Ticker:
- JAGX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
0.41 USD (-18.38%)
Close
Last updated: November 5, 2026
2.12M USD
Market cap
Why the stock is moving
The latest monitored company update is “Jaguar Health Reports Approval of All Proposals at November 2026 Special Meeting of Stockholders.” The corresponding closing-price reaction is not yet available.
Company overview
Plant-Derived Gastrointestinal Medicines
Jaguar Health develops prescription medicines derived from plants for serious gastrointestinal disorders. Its Napo subsidiaries lead development and commercialization of crofelemer for rare intestinal-failure conditions.
Crofelemer Mechanism
Crofelemer is a plant-derived antisecretory medicine that modulates intestinal chloride channels. By reducing excessive fluid secretion without slowing intestinal motility, it is being developed for diseases characterized by severe diarrhea or high ostomy output.
Rare Intestinal Failure Focus
The development program targets short bowel syndrome with intestinal failure and microvillus inclusion disease. Patients with these conditions may depend on prolonged parenteral nutrition and intravenous fluids because the intestine cannot absorb adequate nutrients, electrolytes, and water.
Adult Short Bowel Syndrome Program
Jaguar is evaluating oral crofelemer in adults with Type 1 short bowel syndrome. An open-label pilot study measures ostomy output and parenteral-support requirements, while a randomized Phase 2 study is intended to provide controlled efficacy data.
Pediatric MVID Development
The company is also developing crofelemer for pediatric patients with microvillus inclusion disease, an ultra-rare congenital cause of intestinal failure. The program is designed around reductions in parenteral-support dependence and evidence generated from ongoing patient treatment.
Future catalysts
- Planned NDA filing for crofelemer in microvillus inclusion disease in mid-2027.
- Results from the Phase 2 study of crofelemer in adults with Type 1 short bowel syndrome early in the second half of 2027.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Jaguar Health (JAGX)?
Jaguar Health (JAGX) most recently closed at 0.41 USD, a -18.38% move versus the previous session.
What is the market cap of Jaguar Health (JAGX)?
Jaguar Health currently has a market capitalization of 2.12M USD on BioPharmSignal.
What does Jaguar Health do?
Plant-Derived Gastrointestinal Medicines Jaguar Health develops prescription medicines derived from plants for serious gastrointestinal disorders. Its Napo subsidiaries lead development and commercialization of crofelemer for rare intestinal-failure conditions. Crofelemer Mechanism Crofelemer is a plant-derived antisecretory medicine that modulates...
On which exchange is JAGX stock listed?
Jaguar Health (JAGX) is associated with NASDAQ, United States, Biopharma.
What is Plant-Derived?
Plant-Derived Gastrointestinal Medicines Jaguar Health develops prescription medicines derived from plants for serious gastrointestinal disorders.
Which conditions is Jaguar Health targeting with Plant-Derived?
Plant-Derived Gastrointestinal Medicines Jaguar Health develops prescription medicines derived from plants for serious gastrointestinal disorders. Its Napo subsidiaries lead development and commercialization of crofelemer for rare intestinal-failure conditions. Crofelemer Mechanism Crofelemer is a plant-derived antisecretory medicine that modulates...
How does Jaguar Health describe recent progress with Plant-Derived?
Planned NDA filing for crofelemer in microvillus inclusion disease in mid-2027. Results from the Phase 2 study of crofelemer in adults with Type 1 short bowel syndrome early in the second half of 2027.
What is Gastrointestinal?
Plant-Derived Gastrointestinal Medicines Jaguar Health develops prescription medicines derived from plants for serious gastrointestinal disorders.